Clinical trials: Cancer Colon
Renal Cell Cancer, Melanoma
Study of PF-07263689 in Participants With Selected Advanced Solid Tumors
This is a first-in-human, Phase 1, open label, multicenter, multiple dose, dose escalation and expansion study intended to evaluate the safety, viral load kinetics and shedding, pharmacodynamic, and anti-tumor activity of…
- Conditions
- Renal Cell Cancer, Melanoma, Non-Small-Cell Lung Cancer, Hepatocellular Cancer
- Trial name
- NCT05061537
- Testing
- PF-07263689, Sasanlimab
- Where
- 3 sites in United States
- Volunteers
- 13 people
- Sponsor
- Pfizer
Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1.
This study was conducted to advance new treatment for patients with metastatic or locally advanced cancers expressing Neurotensin receptor 1 (NTSR1).
- Conditions
- Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Gastric Cancer, Squamous Cell Carcinoma of the Head and Neck
- Trial name
- NCT03525392
- Testing
- 177Lu-3BP-227 (also called 177Lu-IPN01087)
- Where
- 8 sites in United States, Belgium and 3 more
- Volunteers
- 14 people
- Sponsor
- Ipsen
Cancer, Neuroendocrine
Study of JI-101 in Patients With Advanced Low Grade Endocrine Tumors, Ovarian Cancers or K-RAS Mutant Colon Cancers
The study consists of two parts: Drug Interaction (Pharmacokinetic) Phase and Pharmacodynamic Phase The primary study objective for the Drug Interaction Study is to determine the pharmacokinetic interactions between RAD001 and…
- Conditions
- Cancer, Neuroendocrine, Ovarian Cancer, Colon Cancer
- Trial name
- NCT01149434
- Testing
- JI-101, Everolimus
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Utah
Colorectal Cancer, Neoplasms, Colorectal
Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy
This phase 2, randomized, active-controlled, open-label, parallel group, multicenter study will be conducted at up to 18 study centers in the US, Central America, and South America.
- Trial name
- NCT00967616
- Testing
- CS7017, irinotecan, leucovorin, and 5-fluorouracil (5-FU) (FOLFIRI)
- Where
- 18 sites in United States, Argentina and 3 more
- Volunteers
- 100 people
- Sponsor
- Daiichi Sankyo
Colorectal Neoplasms, Colonic Polyps
Study of Flat Polyp Detection Using New Narrow Band Imaging (NBI) Compared to White Light Colonoscopy - The FIND FLAT Colonoscopy Study
We hypothesize that high definition narrow band imaging (NBI) colonoscopy compared to high definition white light colonoscopy will detect an increased number of nonpolypoid (flat and depressed) colorectal neoplasm.
- Conditions
- Colorectal Neoplasms, Colonic Polyps, Colorectal Cancer
- Trial name
- NBI (NCT01310699)
- Testing
- Olympus Colonoscope CFHQ190AL
- Where
- 3 sites in United States
- Volunteers
- 281 people, healthy volunteers welcome
- Sponsor
- VA Palo Alto Health Care System
Untreated Metastatic Colorectal Cancer
Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer
This was a blinded, randomized, placebo-controlled Phase 2 multicenter study evaluating the efficacy and tolerability of veliparib plus irinotecan, fluorouracil, and leucovorin chemotherapy regimen (FOLFIRI) compared to placebo…
- Trial name
- NCT02305758
- Testing
- Veliparib, Modified FOLFIRI, FOLFIRI
- Volunteers
- 130 people
- Sponsor
- AbbVie
Colorectal Cancer
Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status
This study is being carried out to see if the new drug, olaparib (AZD2281), can effectively and safely treat advanced large bowel cancer.
- Trial name
- NCT00912743
- Testing
- olaparib
- Where
- 8 sites in United States
- Volunteers
- 33 people
- Sponsor
- AstraZeneca
Metastatic Colorectal Cancer
A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer
This was a randomized, placebo-controlled, double-blind study of vismodegib (GDC-0449) added to biochemotherapy standard-of-care regimens for metastatic colorectal cancer (CRC), with treatment until disease progression.
- Trial name
- NCT00636610
- Testing
- Vismodegib 150 mg, Bevacizumab, Modified FOLFOX
- Volunteers
- 199 people
- Sponsor
- Genentech, Inc.
Colorectal Cancer
Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer
This will be a randomized phase II clinical trial of patients with histologic documentation of metastatic colorectal cancer, who have received local and currently approved standard therapies, excluding RGF.
- Trial name
- NCT02316340
- Testing
- Vorinostat, Hydroxychloroquine, Regorafenib
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Post-Operative Ileus
Asimadoline for the Treatment of Post-Operative Ileus
The purpose of this study is to evaluate the safety and efficacy of asimadoline in patients who have undergone a laparoscopic segmental colectomy and determine whether it reduces the time to recovery of bowel function compared to…
- Trial name
- NCT00443040
- Testing
- Asimadoline
- Where
- 4 sites in United States
- Volunteers
- 35 people
- Sponsor
- Tioga Pharmaceuticals
FGFR1 Gene Amplification, FGFR1 Gene Mutation
Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations
This phase II trial studies how well pemigatinib works in treating patients with colorectal cancer with mutations (alterations) in a FGFR gene and that has spread to other places in the body (metastatic) or cannot be removed by…
- Conditions
- FGFR1 Gene Amplification, FGFR1 Gene Mutation, FGFR1 Gene Translocation, FGFR2 Gene Amplification
- Trial name
- NCT04096417
- Testing
- Pemigatinib, Quality-of-Life Assessment
- Where
- 6 sites in United States
- Volunteers
- 14 people
- Sponsor
- Academic and Community Cancer Research United
Colorectal Cancer
A Study to Assess the Efficacy and Safety of Lenalidomide in Combination With Cetuximab in Pre-treated Patients With KRAS Mutant Colorectal Cancer
The purpose of this study is to determine whether lenalidomide in combination with cetuximab is safe and effective in patients with KRAS mutant colorectal cancer.
- Trial name
- NCT01032291
- Testing
- cetuximab, lenalidomide
- Where
- 17 sites in Australia, Belgium and 4 more
- Volunteers
- 51 people
- Sponsor
- Celgene Corporation
Precancerous Condition
Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps
This randomized phase III trial is studying eflornithine and sulindac to see how well they work compared to a placebo in preventing colorectal cancer in patients with colon polyps.
- Trial name
- NCT00118365
- Testing
- eflornithine, sulindac, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 375 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer
[18F]FLT-PET as a Predictive Imaging Biomaker of Treatment Responses to Regorafenib
Regorafenib is approved in the treatment for metastatic colorectal cancer patients who have been progressed after standard therapies, however, there has not been a predictive biomarker.
- Trial name
- NCT02175095
- Testing
- Regorafenib, [18F]FLT-PET, [18F]FDG-PET
- Where
- South Korea
- Volunteers
- 68 people
- Sponsor
- Asan Medical Center
Metastatic Colorectal Cancer, KRAS Gene Mutation
Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS Mutation
The purpose of the Phase 1b/2 study is to determine the safety and efficacy of Onvansertib, administered orally, daily on Day 1-5 and Day 15-19 of each 28-day cycle, in combination with FOLFIRI + Bevacizumab, as second-line…
- Trial name
- NCT03829410
- Testing
- Onvansertib, Bevacizumab, FOLFIRI
- Where
- 7 sites in United States
- Volunteers
- 68 people
- Sponsor
- Cardiff Oncology
Gastrointestinal Disease, Colorectal Cancer
Evaluation of the Bowel Cleansing in Hospitalized Patients Using Pure-Vu System
The aim of this study is to evaluate the potential improvement in colonoscopy procedure's outcomes when using the Pure-Vu System in hospitalized patients who are indicated for colonoscopy procedure.
- Trial name
- NCT03503162
- Testing
- Pure-Vu System
- Where
- United States
- Volunteers
- 95 people
- Sponsor
- Motus GI Medical Technologies Ltd
Advanced Colorectal Carcinoma, Metastatic Colon Adenocarcinoma
TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study
This phase II trial studies how well TAS-102, irinotecan, and bevacizumab work in treating patients with pre-treated colorectal cancer that has spread to other places in the body (metastatic) or cannot be removed by surgery…
- Conditions
- Advanced Colorectal Carcinoma, Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Recurrent Colon Adenocarcinoma
- Trial name
- NCT04109924
- Testing
- Irinotecan, Bevacizumab, Trifluridine and Tipiracil Hydrochloride
- Where
- 4 sites in United States
- Volunteers
- 42 people
- Sponsor
- Roswell Park Cancer Institute
Pancreatic Cancer, Metastatic Castration-resistant Prostate Cancer
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy
Study of NGM120 in subjects with advanced solid tumors and pancreatic cancer (Part 1 and 2) and metastatic castration resistant prostate cancer (Part 3).
- Conditions
- Pancreatic Cancer, Metastatic Castration-resistant Prostate Cancer, Bladder Cancer, Melanoma
- Trial name
- NCT04068896
- Testing
- NGM120 30mg, NGM120 100mg, NGM120 30mg with Gemcitabine and Abraxane
- Where
- 20 sites in United States
- Volunteers
- 89 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Colon Cancer, Fragility
Prehabilitation of Frail Surgical Cancer Patients Using Remote Ischemic Preconditioning
This project will examine the efficacy of a simple, cost-effective, non-invasive intervention, called remote ischemic preconditioning (RIPC), to reduce frailty in pre-surgical, frail, elderly patients with colon cancer.
- Conditions
- Colon Cancer, Fragility, Prehabilitation, Surgery
- Trial name
- Prehab (NCT03853473)
- Testing
- Remote Ischemic Preconditioning
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Medical College of Wisconsin
Cancer Survivor, Stage I Colorectal Cancer AJCC v8
Systems Support Mapping in Guiding Self-Management in Stage I-III Colorectal Cancer Survivors
This pilot trial studies how well systems support mapping works in guiding self-management in stage I-III colorectal cancer survivors.
- Conditions
- Cancer Survivor, Stage I Colorectal Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8, Stage IIA Colorectal Cancer AJCC v8
- Trial name
- NCT03520283
- Testing
- Interview, Questionnaire Administration, System Support Mapping
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Wake Forest University Health Sciences